Different medications a person living with HIV may take on a daily basis. The first-left image shows a first-line treatment. The middle image shows a second-line therapy for patients who do not respond to first-line therapy. The right image shows a third-line therapy for patients who do not respond to both first- and second-line therapies. Photo credit: Michel Lunanga/MSF
Technical brief |

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

HIV/AIDS
HIV_Q&A_CAB-LA_EN_Nov2023
Report cover image
Photo credit: Michel Lunanga/MSF

This Q&A provides background information and a timeline of MSF’s negotiations with ViiV Healthcare for purchasing and accessing the critical HIV prevention drug cabotegravir long-acting (CAB-LA).

Read, watch, share